AUTL
Autolus Therapeutics plc
$1.46
-4.58%
$388.6M
No data for this timeframe.
Vol
Market Cap$388.6M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders4 funds
Inst. Value$13.3M
Inst. Activity0 buys / 2 sells
SEC Reports4
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. X0·CIK 0001730463·Prev Close $1.53
Recent Activity
Jun 9, 2026
SEC
Autolus Therapeutics published its 2025 UK Annual Report, revealing $55.983M in first-year AUCATZYL US sales, a £222.656
8-K — Impact 7/10
May 14, 2026
SEC
Autolus Therapeutics reported Q1 2026 AUCATZYL net product revenue of $26.2M, up 192% YoY from $9.0M, achieving its firs
8-K — Impact 6/10
May 14, 2026
SEC
Autolus reported Q1 2026 AUCATZYL net product revenue of $26.2M (vs $9.0M YoY), achieving its first positive gross margi
PRESS-RELEASE — Impact 6/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
3,105,404 shares ($6.2M)
Inst.
TWO SIGMA INVESTMENTS, LP — EXIT
0 shares ($0.00)
Jun 9, 2026
short_volume
Short Volume: AUTL — 60.7% short (0.5M / 0.7M)
Short: 450,461 | Exempt: 17,214 | TRF Vol: 741,778 | Short Ratio: 60.7% | Off-exchange volume (dark
May 21, 2026
Press
Autolus Therapeutics released a post-hoc analysis of the Phase Ib/II FELIX study for ASCO, showing obe-cel achieved a 59
Impact 4/10
Apr 21, 2026
Press
Autolus Therapeutics granted stock options for 68,500 ADSs and 57,765 RSUs to 15 new employees as inducement awards unde
Impact 3/10
Price Targets
$8.71
+496.7% upside
Strong Buy
Current $1.46
Low $5.00
Median $10.00
High $11.00
9 analysts
$5.00
$11.00
Analyst Ratings
6Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 14, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 9, 2026 | Needham | REITERATE | Buy → Buy |
| Mar 31, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Mar 27, 2026 | Needham | REITERATE | Buy → Buy |
| Feb 17, 2026 | HC Wainwright & Co. | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.23 ▲ +9.2% | $-0.31 — $-0.18 | -29% YoY | 7 |
| Next Q | $-0.22 ▲ +8.5% | $-0.27 — $-0.18 | 27% YoY | 7 |
| Current FY | $-0.90 ▲ +2.7% | $-1.24 — $-0.56 | 16% YoY | 9 |
| Next FY | $-0.63 ▲ +9.7% | $-0.97 — $-0.43 | 30% YoY | 9 |
Latest Reports
BEARISH
8-K
7/10
Autolus Therapeutics published its 2025 UK Annual Report, revealing $55.983M in first-year AUCATZYL US sales, a £222.656
Jun 9, 2026
NEUTRAL
Press
4/10
Autolus Therapeutics released a post-hoc analysis of the Phase Ib/II FELIX study for ASCO, showing obe-cel achieved a 59
May 21, 2026
MIXED
8-K
6/10
Autolus Therapeutics reported Q1 2026 AUCATZYL net product revenue of $26.2M, up 192% YoY from $9.0M, achieving its firs
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $6.2M | TRIM |
| BANK OF AMERICA CORP | $3.9M | DOUBLED |
| MORGAN STANLEY | $2.8M | DOUBLED |
| WELLS FARGO & COMPANY/MN | $392.2K | TRIM |
4 institutional holders with $13.3M total value (6,660,504 shares) as of 2025-Q4. Top holders: RENAISSANCE, BANK, MORGAN. Net selling activity: 2 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 3,105,404 | $6.2M | 46.6% | TRIM -36.4% |
| 2 | BANK OF AMERICA CORP /DE/ | 1,960,766 | $3.9M | 29.4% | DOUBLED +108.1% |
| 3 | MORGAN STANLEY | 1,397,251 | $2.8M | 21.0% | DOUBLED +162.4% |
| 4 | WELLS FARGO & COMPANY/MN | 197,083 | $392.2K | 3.0% | TRIM -31.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 4,881,372 | 3,105,404 | -36.4% | $6.2M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 172,143 | 0 | -100.0% | $0.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 1,751,200 | 4,881,372 | +178.7% | $8.0M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 975,135 | 2,029,593 | +108.1% | $3.3M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 462,606 | 1,213,773 | +162.4% | $2.0M | 2025-Q3 |
| FMR LLC | EXIT | 7,105,585 | 0 | -100.0% | $0.00 | 2025-Q3 |
| FMR LLC | TRIM | 10,162,348 | 7,105,585 | -30.1% | $16.2M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 32,595 | 975,135 | +2891.7% | $2.2M | 2025-Q2 |
| MORGAN STANLEY | ADD | 309,576 | 462,606 | +49.4% | $1.1M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 395,443 | 146,797 | -62.9% | $334.7K | 2025-Q2 |
| FMR LLC | TRIM | 15,632,270 | 10,162,348 | -35.0% | $15.8M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 618,942 | 1,584,125 | +155.9% | $2.5M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 906,767 | 395,443 | -56.4% | $612.9K | 2025-Q1 |
| UBS Group AG | ADD | 200,232 | 316,227 | +57.9% | $490.2K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 553,134 | 309,576 | -44.0% | $479.8K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 250,871 | 618,942 | +146.7% | $1.5M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 1,817,955 | 553,134 | -69.6% | $1.3M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 385,873 | 266,315 | -31.0% | $625.8K | 2024-Q4 |
| UBS Group AG | ADD | 156,978 | 200,232 | +27.6% | $470.5K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 2,904,843 | 1,817,955 | -37.4% | $6.6M | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 2 mixed, 0 neutral. Avg impact: 6.3/10.
BEARISH
8-K
7/10
Autolus Therapeutics published its 2025 UK Annual Report, revealing $55.983M in first-year AUCATZYL
Jun 9, 2026
MIXED
8-K
6/10
Autolus Therapeutics reported Q1 2026 AUCATZYL net product revenue of $26.2M, up 192% YoY from $9.0M
May 14, 2026
MIXED
PRESS-RELEASE
6/10
Autolus reported Q1 2026 AUCATZYL net product revenue of $26.2M (vs $9.0M YoY), achieving its first
May 14, 2026
BULLISH
8-K
6/10
Autolus Therapeutics held an investor event highlighting real-world data and clinical trial results
Apr 8, 2026
NEUTRAL
4/10
Autolus Therapeutics released a post-hoc analysis of the Phase Ib/II FELIX study for ASCO, showing o
May 21, 2026
NEUTRAL
3/10
Autolus Therapeutics granted stock options for 68,500 ADSs and 57,765 RSUs to 15 new employees as in
Apr 21, 2026
NEUTRAL
3/10
Autolus Therapeutics will announce its Q4 and full-year 2025 financial results on March 27, 2026. Th
Mar 16, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 17 analysts: 6 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.71 mean target
+496.7% upside
Strong Buy (1.11)
$5.00 Low
$11.00 High
| Metric | Value |
|---|---|
| Current Price | $1.46 |
| Target Low | $5.00 |
| Target Mean | $8.71 |
| Target Median | $10.00 |
| Target High | $11.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.11) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.23 | $-0.31 | $-0.18 | -28.8% | +9.2% | 4↑ 0↓ | $0.0B | 44.5% | 7 |
| Next Q 2026-09-30 |
$-0.22 | $-0.27 | $-0.18 | 27.3% | +8.5% | 4↑ 0↓ | $0.0B | 58.0% | 7 |
| Current FY 2026-12-31 |
$-0.90 | $-1.24 | $-0.56 | 16.4% | +2.7% | 5↑ 1↓ | $0.1B | 71.5% | 9 |
| Next FY 2027-12-31 |
$-0.63 | $-0.97 | $-0.43 | 30.0% | +9.7% | 6↑ 1↓ | $0.2B | 49.6% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.232 | |
| 7d ago | $-0.232 | |
| 30d ago | $-0.255 | +0.024 |
| 60d ago | $-0.257 | +0.025 |
| 90d ago | $-0.240 | +0.008 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 14, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 9, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 31, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 27, 2026 | Needham | REITERATE | Buy | Buy |
| Feb 17, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
| Jan 12, 2026 | Needham | MAINTAIN | Buy | Buy |
| Dec 29, 2025 | Needham | MAINTAIN | Buy | Buy |
| Dec 12, 2025 | Needham | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
short_volume
Short Volume: AUTL — 60.7% short (0.5M / 0.7M)
Short: 450,461 | Exempt: 17,214 | TRF Vol: 741,778 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: AUTL — 58.3% short (0.3M / 0.6M)
Short: 334,388 | Exempt: 3,074 | TRF Vol: 573,745 | Short Ratio: 58.3% | Off-exchange volume (dark pool + OTC)
May 27, 2026
other
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus will present and host meetings at two upcoming investor conferences.
May 21, 2026
fda
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
Autolus announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting.
May 14, 2026
earnings
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics announced its operational and financial results for the first quarter ended March 31, 2026.
May 14, 2026
earnings_calendar
AUTL Q1 2026 Earnings Scheduled — 2026-05-14
May 12, 2026
short_volume
Short Volume: AUTL — 57.9% short (0.4M / 0.6M)
Short: 369,935 | Exempt: 400 | TRF Vol: 639,006 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
AUTL Q1 2026 Earnings Scheduled — 2026-05-06
Apr 29, 2026
short_volume
Short Volume: AUTL — 64.0% short (0.5M / 0.8M)
Short: 515,783 | Exempt: 125 | TRF Vol: 806,064 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
activist
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus announces inducement grant awards.
Apr 7, 2026
other
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus will present at upcoming investor conferences.
Apr 1, 2026
Clinical Trial
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Phase Phase 2 — TERMINATED
Mar 27, 2026
earnings
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Autolus announces its operational and financial results for the fourth quarter and full year ended December 31, 2025.
Mar 18, 2026
earnings_calendar
AUTL Q4 2025 Earnings After Market Close — 2026-03-18
Mar 16, 2026
earnings
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
Autolus will announce Q4 and FY 2025 financial results on March 27, 2026.